{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:28:56Z","timestamp":1790702936349,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.anl.2023.11.002","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T15:27:07Z","timestamp":1700926027000},"page":"305-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Understanding hereditary hemorrhagic telangiectasia: From genetic anomalies to systemic manifestations, quality of life, and epistaxis management\u2014Exploring the otolaryngologist's integral role"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7952-0206","authenticated-orcid":false,"given":"Masaki","family":"Hayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1510-9191","authenticated-orcid":false,"given":"Yohei","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Obata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-9663","authenticated-orcid":false,"given":"Takeo","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Inohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2023.11.002_bib0001","first-page":"785","article-title":"Hereditary hemorrhagic telangiectasia: diagnosis and management","volume":"82","author":"Olitsky","year":"2010","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.anl.2023.11.002_bib0002","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu\u2013Osler\u2013Weber syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.anl.2023.11.002_bib0003","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/ajmg.a.35715","article-title":"Hereditary hemorrhagic telangiectasia: how accurate are the clinical criteria?","volume":"161A","author":"van Gent","year":"2013","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.anl.2023.11.002_bib0004","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/humu.10026","article-title":"Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan","volume":"19","author":"Dakeishi","year":"2002","journal-title":"Hum Mutat"},{"key":"10.1016\/j.anl.2023.11.002_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1750-1172-7-33","article-title":"A long diagnostic delay in patients with hereditary haemorrhagic telangiectasia: a questionnaire-based retrospective study","volume":"7","author":"Pierucci","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.anl.2023.11.002_bib0006","doi-asserted-by":"crossref","first-page":"e11687","DOI":"10.1097\/MD.0000000000011687","article-title":"Clinical features and treatment of hereditary hemorrhagic telangiectasia","volume":"97","author":"Li","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.anl.2023.11.002_bib0007","doi-asserted-by":"crossref","first-page":"64","DOI":"10.7248\/jjrhi.58.64","article-title":"Cross-sectional study of the occurrence of epistaxis in HHT patients","volume":"58","author":"Hayama","year":"2019","journal-title":"Nihon Bika Gakkai Kaishi (Jpn J Rhinol)"},{"key":"10.1016\/j.anl.2023.11.002_bib0008","article-title":"A missed case of hereditary hemorrhagic telangiectasia: a case report","volume":"10","author":"Zhang","year":"2022","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.anl.2023.11.002_bib0009","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/ng0294-197","article-title":"A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34","volume":"6","author":"McDonald","year":"1994","journal-title":"Nat Genet"},{"key":"10.1016\/j.anl.2023.11.002_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2015.00001","article-title":"Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era","volume":"6","author":"McDonald","year":"2015","journal-title":"Front Genet"},{"key":"10.1016\/j.anl.2023.11.002_bib0011","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/jmg.2005.030833","article-title":"Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease","volume":"43","author":"Abdalla","year":"2006","journal-title":"J Med Genet"},{"key":"10.1016\/j.anl.2023.11.002_bib0012","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ajhg.2013.07.004","article-title":"BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia","volume":"93","author":"Wooderchak-Donahue","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.anl.2023.11.002_bib0013","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/humu.22431","article-title":"RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformation","volume":"34","author":"Revencu","year":"2013","journal-title":"Hum Mutat"},{"key":"10.1016\/j.anl.2023.11.002_bib0014","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.3390\/ijms24054916","article-title":"The potential role of MiRs-139-5p and -454-3p in endoglin-knockdown-induced angiogenic dysfunction in HUVECs","volume":"24","author":"Cannavicci","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anl.2023.11.002_bib0015","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/cells12121600","article-title":"Generation of a syngeneic heterozygous ACVRL1((wt\/mut)) knockout iPS cell line for the in vitro study of HHT2-associated angiogenesis","volume":"12","author":"Xiang-Tischhauser","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.anl.2023.11.002_bib0016","doi-asserted-by":"crossref","first-page":"13650","DOI":"10.1038\/ncomms13650","article-title":"PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia","volume":"7","author":"Ola","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.anl.2023.11.002_bib0017","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.3390\/ijms19103203","article-title":"Pulmonary arterial hypertension and hereditary haemorrhagic telangiectasia","volume":"19","author":"Vorselaars","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anl.2023.11.002_bib0018","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13023-016-0427-x","article-title":"Life expextancy of parents with hereditary haemorrhagic telangiectasia","volume":"11","author":"de Gussem","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.anl.2023.11.002_bib0019","first-page":"5","article-title":"The importance of a multidisciplinary approach in a patient with long-term multisystemic manifestations of unrecognized hereditary hemorrhagic telangiectasia","volume":"30","author":"Sredoja Ti\u0161ma VS","year":"2022","journal-title":"Acta Dermatovenerol Croat"},{"key":"10.1016\/j.anl.2023.11.002_bib0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13023-016-0533-9","article-title":"20-year follow-up study of Danish HHT patients-survival and causes of death","volume":"11","author":"Kjeldsen","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.anl.2023.11.002_bib0021","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/qjmed\/hcl037","article-title":"Life expectancy in patients with hereditary haemorrhagic telangiectasia","volume":"99","author":"Sabb\u00e0","year":"2006","journal-title":"QJM"},{"key":"10.1016\/j.anl.2023.11.002_bib0022","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.0000000000001538","article-title":"Complications and mortality in hereditary hemorrhagic telangiectasia: a population-based study","volume":"84","author":"Donaldson","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.anl.2023.11.002_bib0023","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.3390\/jcm9113581","article-title":"Hereditary hemorrhagic telangiectasia (HHT) and survival: the importance of systematic screening and treatment in HHT centers of excellence","volume":"9","author":"de Gussem","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.anl.2023.11.002_bib0024","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmg.2009.069013","article-title":"International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia","volume":"48","author":"Faughnan","year":"2011","journal-title":"J Med Genet"},{"key":"10.1016\/j.anl.2023.11.002_bib0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.anl.2023.11.002_bib0026","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3171\/2016.7.JNS16847","article-title":"Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia: a systematic review and meta-analysis","volume":"127","author":"Brinjikji","year":"2017","journal-title":"J Neurosurg"},{"key":"10.1016\/j.anl.2023.11.002_bib0027","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MOO.0000000000000319","article-title":"Comprehensive management of hereditary hemorrhagic telangiectasia","volume":"25","author":"Lupa","year":"2017","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.anl.2023.11.002_bib0028","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13023-020-01579-2","article-title":"Predictors of mortality in patients with hereditary hemorrhagic telangiectasia","volume":"16","author":"Thompson","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.anl.2023.11.002_bib0029","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s11136-004-7865-y","article-title":"Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu\u2013Osler\u2013Weber disease","volume":"13","author":"Pasculli","year":"2004","journal-title":"Qual Life Res"},{"key":"10.1016\/j.anl.2023.11.002_bib0030","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00405-004-0911-0","article-title":"Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire","volume":"262","author":"Karapantzos","year":"2005","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.anl.2023.11.002_bib0031","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.otohns.2006.12.019","article-title":"Health-related quality of life in hereditary hemorrhagic telangiectasia","volume":"136","author":"Geisthoff","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.anl.2023.11.002_bib0032","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anl.2023.11.002_bib0033","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/alr.21374","article-title":"The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia","volume":"4","author":"Merlo","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.anl.2023.11.002_bib0034","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lary.25669","article-title":"The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia","volume":"126","author":"Yin","year":"2016","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anl.2023.11.002_bib0035","first-page":"516","article-title":"FID Score: an effective tool in hereditary haemorrhagic telangiectasia - related epistaxis","volume":"58","author":"Pagella","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.anl.2023.11.002_bib0036","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaoto.2020.3040","article-title":"Development and validation of the nasal outcome score for epistaxis in hereditary hemorrhagic telangiectasia (NOSE HHT)","volume":"146","author":"Peterson","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.anl.2023.11.002_bib0037","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1080\/00016480802468138","article-title":"Impact of genotype and mutation type on health-related quality of life in patients with hereditary hemorrhagic telangiectasia","volume":"129","author":"Pfister","year":"2009","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.anl.2023.11.002_bib0038","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13023-022-02426-2","article-title":"Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT","volume":"17","author":"Le","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.anl.2023.11.002_bib0039","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/bloodadvances.2022007748","article-title":"Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument","volume":"6","author":"Kasthuri","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.anl.2023.11.002_bib0040","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.2016.11387","article-title":"Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial","volume":"316","author":"Dupuis-Girod","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.anl.2023.11.002_bib0041","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2016.11724","article-title":"Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial","volume":"316","author":"Whitehead","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.anl.2023.11.002_bib0042","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jamaoto.2020.3025","article-title":"Efficacy of timolol in a novel intranasal thermosensitive gel for hereditary hemorrhagic telangiectasia-associated epistaxis: a randomized clinical trial","volume":"146","author":"Peterson","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.anl.2023.11.002_bib0043","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2014.06.012","article-title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study","volume":"134","author":"Geisthoff","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.anl.2023.11.002_bib0044","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease","volume":"12","author":"Gaillard","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.anl.2023.11.002_bib0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/anae.12910","article-title":"The current place of tranexamic acid in the management of bleeding","volume":"70","author":"Hunt","year":"2015","journal-title":"Anaesthesia"},{"key":"10.1016\/j.anl.2023.11.002_bib0046","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/lsm.23147","article-title":"Laser-assisted control of epistaxis in hereditary hemorrhagic telangiectasia: a systematic review","volume":"52","author":"Abiri","year":"2020","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.anl.2023.11.002_bib0047","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/alr.21484","article-title":"Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia","volume":"5","author":"Boyer","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.anl.2023.11.002_bib0048","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/lary.29701","article-title":"Sclerotherapy versus cautery\/laser treatment for epistaxis in hereditary hemorrhagic telangiectasia","volume":"132","author":"Woodard","year":"2022","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anl.2023.11.002_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2021.104370","article-title":"The European rare disease network for HHT Frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care","volume":"65","author":"Shovlin","year":"2022","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.anl.2023.11.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2022.103409","article-title":"Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia","volume":"43","author":"Feller","year":"2022","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.anl.2023.11.002_bib0051","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.otohns.2008.01.005","article-title":"Long-term complications of septal dermoplasty in patients with hereditary hemorrhagic telangiectasia","volume":"138","author":"Levine","year":"2008","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.anl.2023.11.002_bib0052","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2500\/ajr.2008.22.3145","article-title":"The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis","volume":"22","author":"Harvey","year":"2008","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.anl.2023.11.002_bib0053","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/00016486409121409","article-title":"Hereditary hemorrhagic telangiectasia: effective treatment of epistaxis by septal dermoplasty","volume":"58","author":"Saunders","year":"1964","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.anl.2023.11.002_bib0054","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/lary.24303","article-title":"A modified technique for septodermoplasty in hereditary hemorrhagic telangiectasia","volume":"124","author":"Rimmer","year":"2014","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anl.2023.11.002_bib0055","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1017\/S0022215100067426","article-title":"Closure of the nostrils in atrophic rhinitis","volume":"81","author":"Young","year":"1967","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.anl.2023.11.002_bib0056","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4193\/Rhin16.315","article-title":"Nasal closure for severe hereditary haemorrhagic telangiectasia in 100 patients. The Lund modification of the Young's procedure: a 22-year experience","volume":"55","author":"Lund","year":"2017","journal-title":"Rhinology"},{"key":"10.1016\/j.anl.2023.11.002_bib0057","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2500\/ajra.2012.26.3809","article-title":"The Young's procedure for severe epistaxis from hereditary hemorrhagic telangiectasia","volume":"26","author":"Richer","year":"2012","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.anl.2023.11.002_bib0058","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/lio2.157","article-title":"The effects of nasal closure on quality of life in patients with hereditary hemorrhagic telangiectasia","volume":"3","author":"Thomson","year":"2018","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.anl.2023.11.002_bib0059","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2133.2010.09848.x","article-title":"Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action","volume":"163","author":"Storch","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anl.2023.11.002_bib0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1160\/TH11-11-0809","article-title":"Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia","volume":"108","author":"Albinana","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.anl.2023.11.002_bib0061","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.anl.2015.12.001","article-title":"Topical application of timolol decreases the severity and frequency of epistaxis in patients who have previously undergone nasal dermoplasty for hereditary hemorrhagic telangiectasia","volume":"43","author":"Ichimura","year":"2016","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.anl.2023.11.002_bib0062","doi-asserted-by":"crossref","first-page":"11986","DOI":"10.1038\/s41598-019-48502-9","article-title":"Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial","volume":"9","author":"Dupuis-Girod","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.anl.2023.11.002_bib0063","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/CH-211253","article-title":"TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT) - study protocol of the prospective, randomized, double-blind, controlled cross-over TIM-HHT trial","volume":"80","author":"Andorfer","year":"2022","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.anl.2023.11.002_bib0064","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103130","article-title":"Topical propranolol improves epistaxis control in hereditary hemorrhagic telangiectasia (HHT): a randomized double-blind placebo-controlled trial","volume":"9","author":"Mei-Zahav","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.anl.2023.11.002_bib0065","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00277-006-0147-8","article-title":"Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab","volume":"85","author":"Flieger","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.anl.2023.11.002_bib0066","first-page":"242","article-title":"Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series","volume":"57","author":"Rosenberg","year":"2019","journal-title":"Rhinology"},{"key":"10.1016\/j.anl.2023.11.002_bib0067","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.anl.2023.11.002_bib0068","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-018-0982-4","article-title":"Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia","volume":"14","author":"Buscarini","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.anl.2023.11.002_bib0069","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/hed.23655","article-title":"Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial","volume":"37","author":"Riss","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.anl.2023.11.002_bib0070","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/alr.22961","article-title":"Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization","volume":"12","author":"Khanwalkar","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.anl.2023.11.002_bib0071","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3892\/etm.2022.11493","article-title":"An in vitro study on the effect of bevacizumab on endothelial cell proliferation and VEGF concentration level in patients with hereditary hemorrhagic telangiectasia","volume":"24","author":"Sadick","year":"2022","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.anl.2023.11.002_bib0072","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10456-021-09807-4","article-title":"Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia","volume":"25","author":"Parambil","year":"2022","journal-title":"Angiogenesis"},{"key":"10.1016\/j.anl.2023.11.002_bib0073","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nm.2131","article-title":"Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia","volume":"16","author":"Lebrin","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.anl.2023.11.002_bib0074","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4193\/Rhino14.289","article-title":"Follow-up of thalidomide treatment in patients with hereditary haemorrhagic telangiectasia","volume":"53","author":"Hosman","year":"2015","journal-title":"Rhinology"},{"key":"10.1016\/j.anl.2023.11.002_bib0075","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1182\/blood-2019-127344","article-title":"Pomalidomide reduces bleeding and alters expression of angiogenesis-related proteins in patients with hereditary hemorrhagic telangiectasia","volume":"134","author":"Swaidani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.anl.2023.11.002_bib0076","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/hmg\/ddx358","article-title":"Tacrolimus rescues the signaling and gene expression signature of endothelial ALK1 loss-of-function and improves HHT vascular pathology","volume":"26","author":"Ruiz","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.anl.2023.11.002_bib0077","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.hoc.2019.01.011","article-title":"Vascular anomalies: diagnosis of complicated anomalies and new medical treatment options","volume":"33","author":"Adams","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.anl.2023.11.002_bib0078","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/lt.21990","article-title":"Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study","volume":"16","author":"Dupuis-Girod","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.anl.2023.11.002_bib0079","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13023-019-1281-4","article-title":"Future treatments for hereditary hemorrhagic telangiectasia","volume":"15","author":"Robert","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.anl.2023.11.002_bib0080","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.0954-6820.1981.tb11614.x","article-title":"Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial","volume":"209","author":"Vase","year":"1981","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.anl.2023.11.002_bib0081","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s13023-022-02539-8","article-title":"Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia","volume":"17","author":"Thompson","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.anl.2023.11.002_bib0082","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10456-020-09758-2","article-title":"Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study","volume":"24","author":"Kroon","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1016\/j.anl.2023.11.002_bib0083","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","article-title":"Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study","volume":"2","author":"Invernizzi","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.anl.2023.11.002_bib0084","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.anl.2023.11.002_bib0085","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00277-013-1845-7","article-title":"Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120","volume":"93","author":"Geisthoff","year":"2014","journal-title":"Ann Hematol"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814623001906?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814623001906?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:40:34Z","timestamp":1759952434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814623001906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0385814623001906"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2023.11.002","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding hereditary hemorrhagic telangiectasia: From genetic anomalies to systemic manifestations, quality of life, and epistaxis management\u2014Exploring the otolaryngologist's integral role","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2023.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}